Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
Phathom has drawn $40 million upon the closing of the amendment, aggregating to $140 million currently outstanding under the expanded loan facility.
- Phathom has drawn $40 million upon the closing of the amendment, aggregating to $140 million currently outstanding under the expanded loan facility.
- The new increased commitment from Hercules reflects our dedication to Phathom and is intended to support their efforts to make their novel treatments available to patients,” said Michael Dutra, Managing Director at Hercules Capital.
- Under the terms of the amendment, the remaining $160 million of the aggregate $300 million loan facility is potentially available in five tranches.
- Additional details of the loan agreement will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K.